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Streptococcus pneumoniae serotype 3 genotypes 
in invasive isolates from Colombia
Zonia Katerin Alarcón, Carolina Duarte, Olga Sanabria, Jaime Moreno
Grupo de Microbiología, Instituto Nacional de Salud, Bogotá, D.C., Colombia
Introduction: Streptococcus pneumoniae serotype 3 is an important cause of pneumonia, 
bacteremia, and meningitis. 
Objective: To establish the circulating genotypes of S. pneumoniae serotype 3 isolates 
recovered from the invasive disease between 1994 to 2015 in Colombia.
Materials and methods: Of the 365 S. pneumoniae serotype 3 isolates recovered through 
the laboratory national surveillance program, 117 isolates were analyzed. Pulsed-field gel 
electrophoresis was used for genotyping, and multilocus sequence typing was determined 
in representative isolates.
Results: The frequency of this serotype increased from 2.7% between 1994 and 1998 to 
9.1% between 2011 and 2015 (p=0.000); 91.7% of the isolates showed a genetic similarity 
greater than 77% and were related to the Netherlands3-31(PMEN31) clone CC180. Several 
subtypes were identified, two of which showed antimicrobial resistance.
Conclusion: In Colombia, the pneumococcal population of the capsular type 3 shows a 
continuous and homogeneous circulation relating to the clonal group ST-180.
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Genotipos del serotipo 3 de Streptococcus pneumoniae en aislamientos invasivos en 
Colombia
Introducción. El serotipo 3 de Streptococcus pneumoniae es una causa importante de 
neumonía, bacteriemia y meningitis.
Objetivo. Establecer los genotipos circulantes de aislamientos del serotipo 3 de S. 
pneumoniae recuperados de muestras de enfermedad invasiva de 1994 a 2015 en 
Colombia.
Materiales y métodos. Se analizaron 117 de los 365 aislamientos del serotipo 3 de S. 
pneumoniae recuperados del programa nacional de vigilancia por el laboratorio. El genotipo 
se estableció con electroforesis en gel de campo pulsado y la tipificación se llevó a cabo 
mediante secuenciación multilocus en aislamientos representativos.
Resultados. La frecuencia de este serotipo aumentó de 2,7 % entre 1994 y 1998 a 9,1 % 
entre 2011 y 2015 (p=0,000). El 91,7 % de los aislamientos evidenció una similitud genética 
superior al 77 % y se relacionó con el clon CC180 de Netherlands3-31 (PMEN31). Se 
identificaron varios subtipos, dos de los cuales mostraron resistencia a los antimicrobianos.
Conclusión. En Colombia, la población neumocócica del tipo capsular 3 tiene una 
circulación continua y homogénea relacionada con el grupo clonal ST-180.
Palabras clave: Streptococcus pneumoniae; Colombia; electroforesis en gel de campo 
pulsado; Colombia.
Streptococcus pneumoniae causes serious invasive diseases such 
as pneumonia and meningitis in young children worldwide (1). In 2015, 
the worldwide mortality rate due to S. pneumoniae was 45 deaths per 
100,000 children from one to 59 months. A global study of the burden of S. 
pneumoniae disease in children estimated 294,000 cases for the Americas 
during the period 2010 to 2015, of which 5,700 died, however, an average 
annual reduction of 8% in deaths was observed related to the use of 
pneumococcal conjugate vaccines (2).
Pneumococcal capsule allows the bacterium to be classified in more than 100 
serotypes according to its antigenic composition (3). Streptococcus pneumoniae 
serotype 3 is characterized by its high virulence, great invasive capacity, high 
mortality, and susceptibility to clinical antibiotics (4). Molecular typing studies of 
S. pneumoniae serotype 3 have shown low genetic diversity among the isolates, 
which is associated with the short duration of nasopharyngeal carriage and its 
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enabled the identification of the Netherlands3-31(PMEN31) clone CC180 as the 
predominant lineage for this serotype (6,7) demonstrating its distribution and 
clonality in different parts of the world such as Japan (8), Denmark (9), North 
America (10), South America (11), and South Africa (12).
Since 1994, Colombia has been monitoring the distribution of serotypes 
and antimicrobial susceptibility of invasive diseases isolates recovered from 
children under five years old. This program was extended in 1996 to the 
general population, thus forming a single national surveillance program that is 
part of the Latin America Network Surveillance System for the Bacterial Agents 
Responsible for Pneumonia and Meningitis (SIREVA II) project (13,14). Based 
on reports from 2006 to 2018, S. pneumoniae type 3 in Colombia represents 
6.37% of isolates recovered in children under 5 years old and 10.77% in adults 
(15). Published data describing the distribution of serotypes during 2000 and 
2010 consigned that serotype 3 was associated with 5.5% (98/1,775) invasive 
isolates and presented an increasing frequency of 4.4% in the years 2007 to 
2008 to 7.2% from 2009 to 2010 (p=0.01) (16). Colombia adopted the PCV10 
universal vaccination in 2011 in a 2 + 1 scheme at 2, 4, and 12 months for 
children less than one-year-old through the public health system (17).
The aim of this study was to establish the genetic relationships of S. 
pneumoniae serotype 3 isolates causing invasive diseases recovered from 
1994 to 2015 to provide information and knowledge about the structure of the 
population.
Materials and methods
From 1994 to 2015, we recovered 365 S. pneumoniae serotype 3 invasive 
isolates from laboratory surveillance. The isolates were typified using the 
Quellung reaction and the antimicrobial susceptibility to penicillin, ceftriaxone, 
chloramphenicol, trimethoprim-sulfamethoxazole, vancomycin, erythromycin, 
and tetracycline was determined by both the disk diffusion method (Kirby-
Bauer) and broth microdilution to determine minimal inhibitory concentrations 
(MIC) according to the criteria of the Clinical and Laboratory Standards 
Institute (CLSI) guidelines for each year (18). Isolates were sent mainly from 
Bogotá (44.4%), Antioquia (21.4%), and Valle del Cauca (9.3%), and the 
remaining 21.1% from other 20 political divisions.
We calculated a representative sample of the 365 isolates with the 
formula for the point estimate of prevalence assuming a prevalence of 50%, a 
maximum expected difference of 15% (± 7.5%), and an alpha error of 5%. The 
representative sample was 117 isolates, of which 95 were randomly selected 
proportionally to the frequencies observed in each year and 22 that presented 
resistance to at least one antibiotic.
Genotyping was carried out by pulsed-field gel electrophoresis (PFGE) 
using the SmaI restriction enzyme. The R6 strain and 12 international clones 
of the Pneumococcal Molecular Epidemiology Network (PMEN) including the 
Netherlands3-31(PMEN31) clone CC180 were used as controls (6,19). The 
electrophoretic patterns were analyzed using the GelCompar program for 
generating dendrograms and ≥75% genetic similarity was assumed for the 
definition of clonality (19). Five isolates were selected according to the analysis 
of the dendrogram generated by PFGE for molecular typing by multilocus 
sequence typing (MLST) performed following the protocol of Enright, et al. 
(20). The sequence type of each isolate was determined using the software 
available on the MLST website (https://pubmlst.org/spneumoniae/). 
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Statistical analysis
We made a descriptive analysis. Variables were described using relative 
or absolute frequencies of the demographic and clinical variables of the S. 
pneumoniae serotype 3 isolates. For the frequency of serotype 3, the data 
were grouped into four periods, two of five years: 1994-1998, 1999-2003, and 
two of six years: 2004-2009, 2010-2015. The relationships or associations 
between the variables were evaluated using the c2 or Fisher’s test. An 
association was considered significant if it had a value of p≤0.05. The Epi-Info 
7 statistical program was used.
Results
The 365 isolates of serotype 3 represented 6.1% of the total isolates 
received during the period under study; their distribution over time periods 
is shown in table 1. We observed a significant difference in the frequency of 
serotype 3 isolates, which increased from 2.7% (20/741) in 1994-1998 to 9.1% 
(223/2,448) in 2010-2015 (p=0.000). In children under five years the frequency 
was 3.3% (30/902) while in patients over 50 it was 11.9% (173/1,449). The 
main diagnosis of patients with serotype 3 was pneumonia (n=132, 36.2%) 
followed by sepsis (n=100, 27.4%). From all the pneumonia cases, serotype 
3 was identified in 6.5% (132/2030) of them, and in sepsis cases, it was 
recovered in 9.5% (100/1,404) (table 1). 
As regards the seven antibiotics evaluated, the 365 isolates were 
susceptible to penicillin, ceftriaxone, and vancomycin. Twenty-two isolates 
were resistant to at least one antibiotic (chloramphenicol, trimethoprim-
sulfamethoxazole, erythromycin, and tetracycline), four of which had reduced 
susceptibility to penicillin (MIC=0.125 µg/ml) and six were multi-resistant (to 
chloramphenicol, erythromycin, and tetracycline) (table 2).
From the 117 isolates characterized by PFGE, 107 (91.4%) were grouped in 
electrophoretic pattern A with 13 subtypes (A1-A13), they had genetic similarity 
greater than 77%, and were related to the Netherlands3-31-ST-180 clone (table 2 
and supplementary figure). Subtype A1 grouped 35/107 (32.7%) isolates with a 
98% similarity of which 26/35 (74.2%) were recovered between 2010 and 2015 
mainly from patients with pneumoniae (n=12, 34.2%) and adults over 50 years 
(n=13, 37.1%). Only one isolate showed reduced susceptibility to penicillin. 
As regards subtype A2, 26/107 (24.3%) isolates had a 96.7% genetic 
similarity and were recovered mainly in the last two periods under study: 
2004-2015 (n=21, 80.7%) from patients over 50 years old (n=12, 46.2%) 
with pneumonia diagnosis (n=10, 38.4%) and one isolate showed reduced 
susceptibility to penicillin. 
Table 1. Distribution of and Streptococcus pneumoniae serotype 3 isolates recovered from surveillance in Colombia, 1994-2015
MBA: Bacterial meningitis, ND: No data 
Streptococcus 
pneumoniae
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Subtype A3 with 8/107 (7.4%) isolates had a 96.8% genetic similarity. All 
the isolates were susceptible to the antibiotics evaluated. 
Subtype A4 was found in 8/107 (7.4%) isolates with a 100% similarity, 
mostly recovered from 2010 to 2015 of adults over 50 years (n=6, 75%) and 
patients with pneumonia (n=4 50%). Three isolates had resistance to two 
antibiotics (two to chloramphenicol and tetracycline and one to erythromycin 
and tetracycline) while five isolates (62.5%) were multiresistant to 
chloramphenicol, erythromycin, and tetracycline. The isolates were recovered 
in different political divisions. 
Subtype A5 was identified in 7/107 (6.5%) isolates with a 93% genetic 
similarity; all of them were resistant to at least one of the antibiotics evaluated. 
Subtype A6 grouped 5/107 (4.6%) isolates with a 91% similarity. 
Subtypes A7-A13 were identified in 18/107 (16.8%) isolates, all of which were 
susceptible to the antibiotics. One isolate of subtypes A1, A2, A4, A5, and A6 
was selected by MLST. ST180 was identified in subtypes A1, A2, A4, and A5. 
In A6, the isolate was related to ST-9162, a single locus variant in the aroE 
allele of ST-180 (supplementary figure).
Discussion
In Colombia, serotype 3 represents 6.1% of isolates recovered from 
invasive diseases, most are susceptible to antibiotics for clinical use and 
were isolated mainly from patients over 50 years. The molecular typing of the 
isolates characterized in this study showed genetic homogeneity related to the 
Netherlands3-31/ST180 clone.
Data analyses of SIREVA II reports from 2000 to 2014 (21) was performed 
to establish the frequencies of serotype 3 in the region. According to the 
Table 2. Distribution of the restriction patterns of Streptococcus pneumoniae serotype 3 isolates received in the surveillance program in Colombia, 1994-2015
MBA: Bacterial meningitis; ND: No data; NR: Not related; RSP: reduced susceptibility to penicillin; Chlor: Chloramphenicol; STX: Trimetroprim-sulfamethoxazole; Ery: Erythromycin; 
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A1 35 1 2 6 26 4 6 1 8 13 3 9 12 10 1 3 34 1 0 0 0   0 0 180
A2 26 2 3 11 10 5 4 2 2 12 1 5 10 6 5 25 1 0 0 0   0 0 180
A3 8 3 1 4 3 1 3 1 4 3 1   8 0 0 0 0   0 0 -
A4 8 8 1 6 1 1 4 2 1   0 0 7 0 6   8 5 180
A5 7 2 1 4 2 2 2 1 1 3 1 2   0 0 0 2 1   4 0 180
A6 5 5 2 1 2 3 1 1   5 0 0 0 0   0 0 9162
A7 4 1 3 2 1 1 2 1 1   4 0 0 0 0   0 0 -
A8 4 1 1 2 4 1 1 1 1   3 0 0 0 0   1 0 -
A9 3 1 1 1 1 1 1 1 1 1   3 0 0 0 0   0 0 -
A10 3 1 2 2 1 2 1   3 0 0 0 0   0 0 -
A11 2 1 1 1 1 2   2 0 0 0 0   0 0 -
A12 1 1 1 1   1 0 0 0 0   0 0 -
A13 1 1 1 1   1 0 0 0 0   0 0 -
B 3 1 1 1 1 1 1 2 1   0 1 0 1 0   3 1 -
C 2 2 2 1 1   1 1 0 0 0   0 0 -
D 2 2 1 1 2   2 0 0 0 0   0 0 -
NR 3 1 1 1 1 1 1 1 2   3 0 0 0 0   0 0 -
Total n 117 8 13 24 72 25 14 8 17 46 7 26 44 27 12 8 95 4 7 3 7 16 6 ST: 180 
9162
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analysis, Brazil (7.35%), Chile (5.42%), and México (5.23%) presented similar 
frequencies as those found in Colombia. Higher serotype 3 frequencies 
were observed in Uruguay (10.81%) and Costa Rica (10.32%) while lower 
frequencies were detected in Guatemala (1.42%) and Honduras (0.74%). 
A recent meta-analysis to establish epidemiological data in pediatric 
pneumococcal pneumonia in Latin America from 2000 to 2016 showed low 
frequencies in Paraguay (0.8%) and Chile (0.9%) and high frequencies in 
Uruguay (6.5%) and Venezuela (8.1%) (22).
In the United States, the frequency of pneumococcal disease associated 
with serotype 3 before the introduction of PCV13 was 4% in children and 9% 
in adults (23). In European countries such as Italy, serotype 3 was the most 
frequent in patients above the age of 45 years accounting for 17.3% of the 
isolates (24). In Spain, from 2010 to 2013, serotype 3 was one of the most 
frequent invasive disease serotypes with 12% of isolates recovered from 
children under five years old and 18% from children over five years old (25) 
while in Japan, it was the main serotype with a frequency of 14.7% in isolates 
recovered from adults between 2006 and 2014 (26). 
In this study, S. pneumoniae serotype 3 isolates were recovered mainly 
from patients older than 50 years old (table 1), which is similar to findings 
from other countries that reported the highest frequency in older adults. 
Similarly, serotype 3 was recovered most frequently in patients diagnosed with 
pneumonia (table 1) in agreement with findings from other studies (27,28). 
Capsular type 3 has been associated with complicated pneumonia, empyema, 
and necrotizing pneumonia with high mortality rates in children over five years 
old and adults (27,29,30). The second most frequent diagnosis associated 
with the isolates was sepsis. Sepsis occurs in approximately 30% of cases of 
community-acquired pneumonia (31) and serotype 3 has been independently 
associated with septic shock in patients with pneumococcal pneumonia (32). 
This finding could be related to the ability of capsular type 3 to produce high 
concentrations of capsular polysaccharides to overcome host immunity and 
proliferate more efficiently than other pneumococcal serotypes (28).
Streptococcus pneumoniae serotype 3 is characterized as susceptible to 
most antimicrobials for clinical use (4). In this study, four (1.1%) isolates were 
reduced susceptibility to penicillin (MIC=0.125 - 0.250 μg/ml). Penicillin resistance 
is related to modifications in the amino acid motifs conserved in penicillin-binding 
proteins encoded by the pbp1a, pbp2b, and pbp2x genes (33). Alterations in 
the pbp2x gene have been identified in serotype 3 isolates with intermediate 
penicillin resistance (34). Additionally, a serotype 3 penicillin-resistant isolate 
(MIC=1 μg/ml) was generated by genetic recombination of the capsule locus 3 of 
a susceptible isolate with the Taiwan23F-15 ST-242 clone (35).
We found six multiresistant isolates to tetracycline, chloramphenicol, and 
erythromycin. Resistance to these antibiotics has mainly been associated with 
the tetM, cat, and ermB/Mefe genes, respectively (7,8,36), usually located on 
mobile genetic elements such as Tn916 and Tn5253 (37). Future studies are 
necessary to determine if these mobile elements are present in these isolates.
In Colombia, genetic homogeneity was observed in the serotype 3 isolates 
related to the Netherlands3-31-ST-180 clone. ST-180 is the most frequent 
typing for serotype 3 and is characterized by its susceptibility to antibiotics 
for clinical use and its wide geographical distribution (8,10,11,20). Although 
ST-180 is still the most common, other clonal groups such as ST-458 have 
also been reported for this capsular type, which is the predominant lineage 
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in the serotype 3 isolates recovered in South Africa (12), as well as ST-4909, 
which is the second most frequent sequence type in Mexican isolates (38), 
and ST-260, which was found in 41.9% of serotype 3 isolates in Spain (39). 
Additionally, as a result of possible capsular switching events, the presence 
of capsular type 3 has been reported in other clones of worldwide distribution 
including Spain23F-1-3, Taiwan23F-15-3, Poland6B-20-3, Portugal19F-21-3, 
Spain23F-1-3, Netherlands14-35-3, Netherlands15-37-3, and Netherlands7F-39-3 
(https://pubmlst.org/spneumoniae/).
In spite of the clonality of the isolates of serotype 3, we observed variability 
in electrophoretic patterns that allowed subdivision into subtypes. The subtype 
A1 contained the isolates recovered in the last study period, which suggests 
that this subtype is the one currently circulating and should be evaluated 
if it presents genetic differences favoring its dispersion and successful 
behavior. Subtypes A4 and A5 contained antibiotic-resistant isolates and 
were recovered in recent years. This finding suggests possible genetic 
recombination events through the acquisition of mobile genetic elements 
conferring resistance mechanisms (7). These subtypes may represent 
emerging clonal lineages that could diminish the therapeutic options against 
invasive pneumococcal disease associated with this capsular type. Based on 
the whole-genome analysis, recently, Azarian, et al., described 3 lineages for 
ST180: Clade Iα, clade Iβ, and clade II. Clade II is an emerging lineage that 
is increasing its population size and prevalence of antibiotic resistance by the 
acquisition of Tn916 (40). The subtypes A4 and A5 found in this study may be 
related to this lineage due to its phenotypic and genotypic characteristics.
The global pneumococcal sequencing project (GPS, http://www.
pneumogen.net/gps/) analyzed 20,027 S. pneumoniae genomes and defined 
621 global pneumococcal sequence clusters (GPSC) of which only the 
GPSC12 included susceptible and resistant isolates expressing serotype 3 
and ST180 (41). Here we did not perform whole-genome sequencing to define 
the GPSC of isolates, however, we expect to perform this type of analysis in 
this pneumococcal population in the future.
Our study limitations include the passive surveillance of bacterial 
meningitis and pneumonia, as not all cases can be detected, but it is 
sustainable over time and it provides an overview of the general distribution of 
isolates, as well as important information for monitoring serotypes associated 
with invasive pneumococcal disease circulating in the country.
The present study described the genetic characteristics of the invasive 
serotype 3 isolates in the pneumococcal population in Colombia. It 
demonstrated their clonality and identified predominant subtypes in the 
most recent sample period, which may represent important lineages with 
antimicrobial-resistant characteristics. Therefore, it is necessary to carry out 
continuous monitoring and additional studies to determine the evolution and 
impact of S. pneumoniae serotype 3 isolates.
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